Results 101 to 110 of about 116,963 (259)

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

The role of adrenergic receptor polymorphisms in heart failure

open access: yesBrazilian Journal of Medical and Biological Research, 2006
The main function of the cardiac adrenergic system is to regulate cardiac work both in physiologic and pathologic states. A better understanding of this system has permitted the elucidation of its role in the development and progression of heart failure.
A. Biolo   +6 more
doaj  

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang   +2 more
wiley   +1 more source

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta‐Analysis

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad   +4 more
wiley   +1 more source

The Benefits of Adding Non‐Antimuscarinic Pharmaceuticals in Combination With Beta‐3 Agonists for Overactive Bladder Treatment: A Systematic Review

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Antimuscarinics, as the current first‐line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta‐3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and ...
Felicity Smith   +2 more
wiley   +1 more source

The beta1-adrenergic receptor in the heart. [PDF]

open access: yesCell Death Discov
Xu W   +8 more
europepmc   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

open access: yesObesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu   +5 more
wiley   +1 more source

Atopic dermatitis and attention‐deficit/hyperactivity disorder comorbidity in children and adolescents: Epidemiology, mechanisms, and clinical management

open access: yesPediatric Investigation, EarlyView.
This review synthesizes epidemiological evidence linking atopic dermatitis to attention‐deficit/hyperactivity disorder in children, proposes an “inflammation‐itch‐neurobehavioral axis” integrating sleep disruption, neuroendocrine dysregulation, and emerging neuro‐immune circuits, and outlines multidisciplinary management strategies targeting both skin ...
Qingyang Zhao   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy